

---

Note: This agenda is a convenience document for English speaking shareholders. The official agenda has been drawn up in the Dutch language and shall be governed and construed in accordance with the laws of The Netherlands. This English translation has been made with due care but the translation of certain Dutch terms and notions may not be fully or adequately understood in translation. For that reason in case of differences the official Dutch language document shall prevail and will determine the legal position of the company.



## **Reed Elsevier NV**

# Agenda Annual General Shareholders' Meeting 2008

Thursday, 24 April 2008 from 10.30 a.m. CET  
Hotel Okura, Ferdinand Bolstraat 333, Amsterdam, The Netherlands

# Letter to the shareholders of Reed Elsevier NV

Dear shareholders,

Amsterdam, 20 March 2008

## Annual General Meeting 2008

### Introduction

The Annual General Meeting of Reed Elsevier NV (the 'Company') will be held on Thursday 24 April, 2008 from 10.30 a.m. CET at the Okura Hotel in Amsterdam ('AGM'). The agenda for the meeting and travel directions are attached to this letter.

For attendance and voting at the AGM the requirements set out in the notice of meeting that was published on 20 March 2008 will apply. A copy of the notice is attached to this agenda as Appendix A. The combined board has determined that Thursday, 27 March 2008 shall be the registration date on which shareholders wishing to attend the AGM must be registered as shareholders by banks in the Netherlands admitted by Euroclear Nederland, the Dutch giro institute ([www.euroclear.com](http://www.euroclear.com)). Shareholders who wish to attend the meeting (in person or by proxy) must procure that a bank or broker in the Netherlands associated with Euroclear Netherlands shall inform ABN AMRO Bank N.V. in the Netherlands of their intention to attend the meeting and for what number of shares, no later than Thursday, 17 April 2008.

A proxy form is available from the offices of the Company and from our website ([www.reedelsevier.com](http://www.reedelsevier.com)). Proxy forms should be submitted to the Secretariat of the Company (see contact details at the end of this letter) no later than Monday, 21 April 2008. Shareholders participating in the Shareholder Communication Channel will receive the agenda and a proxy form by mail and have the facility to vote electronically via [www.proxyvote.nl](http://www.proxyvote.nl), by using the control number on the proxy form.

There will be electronic voting at the AGM. For that purpose proxy holders representing different shareholders and who have received voting instructions such that they cannot vote all the shares for which they will be attending in the same manner (for, against, abstention) for each individual agenda item, will need to contact the Secretariat of the Company (see contact details set out at the end of this letter) no later than Monday, 21 April 2008, to enable appropriate processing of those instructions.

In addition to the information in the agenda I will now provide some further explanation in respect of individual agenda items.

### Agenda item 2: Presentation and discussion annual report 2007

Sir Crispin Davis, Reed Elsevier's Chief Executive Officer, will give a presentation of the development of the business and the results achieved in 2007. There will be opportunity for discussion.

### Agenda item 3: Discussion and adoption of the 2007 Annual Financial Statements

The Reed Elsevier Annual Reports and Financial Statements 2007 are available from the Company's website ([www.reedelsevier.com](http://www.reedelsevier.com)). Printed copies can be requested from the Company Secretariat in limited quantities. On account of efficiency considerations it has been decided no longer to publish separate summary annual financial statements, also because the availability of a less voluminous document for mailing purposes has become less of an issue due to online availability of the annual report and financial statements.

### Agenda item 4: Waiver of claims by shareholders in respect of 2007

This annual agenda item concerns the separate waiver of claims against the members of the Executive Board and of the Supervisory Board. Reference is made to the agenda.

**Agenda item 5: Dividend**

The equalised final dividends proposed by the respective boards of Reed Elsevier NV and Reed Elsevier PLC are €0.311 for Reed Elsevier NV and 13.6p for Reed Elsevier PLC, up 2% and 15% respectively on the prior year. Together with the interim dividends paid in 2007, these give total dividends for the year of €0.425 and 18.1p respectively, up 5% for Reed Elsevier NV and 14% for Reed Elsevier PLC on the prior year dividends. The difference in dividend growth rates reflects the movement in the euro/sterling exchange rate between this year's and the prior year's dividend announcement dates.

Dividend cover, based on adjusted earnings per share and the total of the interim and proposed final dividend for the year, was 1.9 times for Reed Elsevier NV and 2.0 times for Reed Elsevier PLC. Reed Elsevier's unchanged dividend policy is that in normal circumstances dividend shall over the longer term be covered at least twice by adjusted earnings per share.

**Agenda item 6: Appointment of external auditors**

The Audit Committee has conducted a formal review of the performance of the external auditors and the effectiveness of the audit. Based on this review, and on their subsequent observations on the planning and execution of the external audit for the year ended 31 December 2007, the Audit Committee has recommended the re-appointment of Deloitte Accountants B.V. as the external auditors of the Company until the Annual General Meeting in 2009. The Supervisory Board follows this recommendation with the support of the Executive Board. Reference is made to the Audit Committees' Report on pages 76-78 of the Annual Report.

**Agenda items 7 and 8: Board changes**

During the year the Corporate Governance Committee, comprising the members of the Supervisory Board (non-executive directors) conducted a review of the functioning and constitution of the boards and the committees, and also retained external consultants to conduct a board effectiveness review. Based on these assessments and the board effectiveness review, the Nominations Committee believes that the performance of each director recommended for re-election at the Annual General Meeting continues to be effective, and that they each demonstrate commitment to their respective roles in Reed Elsevier. Reference is made to the description of the work of the Corporate Governance Committee and the Nominations Committee on pages 45-46 of the Annual Report.

At the end of the Annual General Meeting and in accordance with the rotation schedule Lisa Hook will retire from the Supervisory Board and Sir Crispin Davis, Gerard van de Aast and Andrew Prozes will retire from the Executive Board. Each of the directors retiring by rotation is eligible for re-appointment and has declared to be available for re-appointment. The combined board recommends their re-appointment.

Strauss Zelnick stood down as member of the Supervisory Board and non executive director of Reed Elsevier PLC in December 2007 after three years of service due to his increasing commitments in the US. His wide ranging media experience has benefited us in many ways and we thank him for his insightful contributions.

Rolf Stomberg will be retiring at the conclusion of the Annual General Meeting after nine years of service as a member of the Supervisory Board, as senior independent director of Reed Elsevier and as chairman of the Remuneration Committee. He has been an invaluable board member through a period of significant change for Reed Elsevier and we thank him for his substantial contribution.

Biographical information in relation to the members of the Executive Board and the Supervisory Board recommended for re-appointment appears in Appendix B to the Agenda. In accordance with the articles of association appointments are for a maximum period of three years. Appointments to the Supervisory Board are made in accordance with the profile for that board which is available from the Reed Elsevier website ([www.reedelsevier.com](http://www.reedelsevier.com)).

## Letter to the shareholders of Reed Elsevier NV (continued)

### Agenda item 9: Changes remuneration policy and non-executive fees

Reference is made to the remuneration report on pages 51-75 of the Annual Report. The report contains the information and disclosures under Netherlands and UK requirements and has been reformatted for improved accessibility. Mark Elliott has succeeded Rolf Stomberg as chairman of the Remuneration Committee and his introductory statement on page 52 of the Annual Report explains the considerations of the Committee on proposed changes to executive remuneration.

We ask shareholders to approve these changes as explained by Mr Elliott at agenda item 9(a), in particular:

- An increase of 2% points in the compound annual adjusted EPS growth rates required to meet the performance conditions under the Long Term Incentive Plan (LTIP), the Bonus Investment Plan (BIP) and the Executive Share Option Scheme (ESOS). The minimum EPS growth rates that must be met and, where appropriate, the stretch performance levels that must be achieved for maximum vesting will all increase by 2% points for all awards made in 2008 under these plans. Details are provided under the description of each plan in the remuneration report.
- In addition, to reflect the level of stretch in our budget targets, the target annual bonus opportunity for executive directors will be increased to 100% of salary (from 90% in 2007).

As explained in the remuneration report on page 64 of the Annual Report, an increase in the fees for Reed Elsevier's non-executive directors is proposed at agenda item 9(b) to better align these with fees paid by companies of comparable size and international scope. The fee for Reed Elsevier's Chairman (also Chairman of the Supervisory Board of Reed Elsevier NV) shall remain unchanged. The proposed fees are for the functions of the non-executives as directors of Reed Elsevier NV, Reed Elsevier PLC, Reed Elsevier Group plc and Elsevier Reed Finance BV and also reflect the membership of the unitary boards of the UK companies.

The combined board recommends that the annual general meeting shall approve the proposed amended fees for the members of the Supervisory Board, as follows:

	Annual fee 2008	Annual fee 2007
Chairman	€350,000	€350,000
Non executive directors	€55,000/€75,000	£45,000/€65,000
Additional for chairman of:		
- Audit Committee	€15,000/€20,000	£7,000/€12,000
- Remuneration Committee	€15,000/€20,000	£7,000/€12,000

The fee for Dien de Boer-Kruyt, who is a member of the Supervisory Boards of Reed Elsevier NV, Elsevier Reed Finance BV and Reed Elsevier Nederland BV would be increased to €48,000 (from €33,800 in 2007).

The Reed Elsevier Chairman chairs the Nominations Committee and the Corporate Governance Committee and does not receive a separate fee for his role as chairman of those committees.

**Agenda item 10: Authority for the Executive Board to purchase own shares**

This is an annually recurring agenda item that is intended to give the Executive Board the necessary flexibility to re-purchase shares. The maximum price for own share purchases is described in the agenda. Share purchases shall not exceed or result in a holding by the Company (and/or its subsidiaries taken together) of its own shares in excess of 10% of the issued share capital. The authority will be used only in circumstances where the combined board, after careful consideration, believes that a purchase would result in an expected increase in adjusted earnings per share and would be in the interests of the Company and of its shareholders as a whole.

If approved by shareholders, this authority will enable the Company to continue to operate the annual share repurchase programme, which commenced in 2006. The combined board believes that a continuation of this programme will further improve capital efficiency. The repurchase of shares in the Company and in Reed Elsevier PLC will reflect the equalisation ratio.

Following the share consolidation effective 7 January 2008 there were 658,127,218 ordinary shares of €0.07 each in issue as well as 4,050,720 R-shares of €0.70 each. 30,584,485 ordinary shares of €0.07 (including 8,682,054 held by the Reed Elsevier Group plc employee benefit trust) and 135,179 R-shares of €0.70 were held in treasury.

**Agenda item 11: Authority for the combined board to issue shares, grant share options and restrict pre-emptive rights**

This proposal is also an annually recurring agenda item. Agenda item 11(a) aims at renewing the authority of the combined board to issue shares and to grant share options. The authority is for a period of 18 months and shall be restricted as described in the agenda. The combined board will only use the authority if it is considered that such would be in the interests of the Company and its shareholders.

Agenda item 11(b) is the necessary complement of the first and intends to authorise the combined board to cancel the pre-emptive rights of existing shareholders in respect of share issues or share option grants pursuant to resolutions of the combined board.

I hope that a large proportion of our shareholders will attend the meeting in person or by proxy and we are looking forward to the opportunity to discuss our excellent 2007 results and relevant developments.

The Executive Board and the Supervisory Board consider that all the proposals submitted to the Annual General Meeting are in the best interests of the Company and the shareholders as a whole. The members of the boards recommend you to vote in favour of the proposed resolutions, as they intend to do in respect of their own holdings.

Yours sincerely,

**Jan Hommen**

(Chairman of the Supervisory Board)

Secretariat of Reed Elsevier NV  
P.O. Box 470  
1000 AL Amsterdam  
T +31(0)20 485 2222  
F +31(0)20 485 2032  
website: [www.reedelsevier.com](http://www.reedelsevier.com)

# AGENDA

## ANNUAL GENERAL MEETING

of the shareholders of  
Reed Elsevier N.V.  
established in Amsterdam (the 'Company')  
to be held on Thursday, 24 April 2008 from 10.30 a.m. CET  
at the Okura Hotel in Amsterdam, the Netherlands

An explanation of agenda items is given in the attached letter from the Chairman of the Supervisory Board and in the appendices.

The term 'combined board' as used in this Agenda has the meaning set out in the articles of association of the Company (the 'Articles of Association') and refers to the body corporate consisting of the members of the Executive Board and of the Supervisory Board. The term 'General Meeting' as used in this Agenda has the meaning set out in the Articles of Association and refers to general meeting of shareholders.

The notice for the meeting as published in accordance with the Articles of Association and on the Company's website is attached at Appendix A.

1. **Opening**

2. **Presentation and discussion annual report 2007 and relevant developments**

Reference is made to the various reports on the business and results as contained in the Reed Elsevier Annual Report and Financial Statements 2007. Copies can be obtained from the office of the Company and are available at the Company's website. A presentation will be given at the general meeting and there will be opportunity for discussion.

3. **Discussion and adoption of the 2007 Annual Financial Statements**

The Company's 2007 Annual Financial Statements are included in and constituted by the Reed Elsevier Annual Reports and Financial Statements 2007. These have been audited by Deloitte Accountants BV, who have issued an unqualified opinion and who will be present during the meeting to answer questions.

4. **Waiver of claims against the members of the Executive Board and of the Supervisory Board ('Kwijting')**

(a) In accordance with Article 31.2 of the Articles of Association, the General Meeting is requested to waive claims against the members of the Executive Board in respect of their functioning and in particular their management during the 2007 financial year.

(b) In accordance with Article 31.2 of the Articles of Association, the General Meeting is requested to waive claims against the members of the Supervisory Board in respect of their functioning and in particular the supervision of management during the 2007 financial year.

5. **Dividend**

Subject to adoption of the 2007 Annual Financial Statements by the General Meeting, the combined board recommends a 2007 final dividend of €0.311 per ordinary share of € 0.07. Taking into account the €0.114 interim dividend per ordinary share that was paid on 24 August 2007, this means that the 2007 total dividend per ordinary share amounts to €0.425. The final dividend will be payable on 16 May 2008 and the ordinary shares will trade ex-(final) dividend from 28 April 2008.

6. **Appointment of external auditors**

In pursuance of the recommendation made by the Audit Committee, it is proposed by the Supervisory Board that the Company's current external auditors, Deloitte Accountants BV, be appointed as external auditors of the Company until the Annual General Meeting in 2009, under terms and conditions to be determined by the Supervisory Board. The principal considerations underlying this recommendation are set out in the letter from the Chairman of the Supervisory Board.

7. **Changes in the Supervisory Board**

7(a) Re-appointment Lisa Hook

As per the rotation schedule adopted by the combined board, Lisa Hook will stand down from the Supervisory Board at the end of the meeting. In accordance with a recommendation of the Nominations Committee, it is recommended by the combined board that she be re-appointed.

Reference is made to the letter from the Chairman of the Supervisory Board, which contains the considerations of the combined board for this recommended re-appointment. The recommendation reflects the profile for the Supervisory Board that is available from the Company's website ([www.reedelsevier.com](http://www.reedelsevier.com)).

In accordance with the Articles of Association, appointments to the Supervisory Board are for a maximum period of 3 years. Miss Hook is eligible and has stated her willingness to accept a re-appointment. The relevant personal details as referred to in Article 21.4 of the Articles of Association are set out in Appendix B to this agenda.

8. **Changes in the Executive Board**

8(a) Re-appointment Sir Crispin Davis

8(b) Re-appointment Gerard van de Aast

8(c) Re-appointment Andrew Prozes

As per the rotation schedule adopted by the combined board, Sir Crispin Davis, Gerard van de Aast and Andrew Prozes will stand down as members of the Executive Board at the end of the meeting. In accordance with a recommendation from the Nominations Committee, they are recommended for (re-)appointment by the combined board. Voting on these recommendations will be separate for each of the candidates.

The considerations for the above recommendations by the combined board are set out in the attached letter of the Chairman of the Supervisory Board. In accordance with the Articles of Association, appointments to the Executive Board are for a maximum period of 3 years. All candidates recommended for appointment to the Executive Board are eligible and have stated their willingness to accept an appointment. The relevant personal details of the candidates as referred to in Article 15.3 of the Articles of Association are set out in Appendix B to this agenda.

9. **Changes to remuneration policy and fees non-executive directors**

Reference is made to the remuneration report on pages 51-75 of the Annual Report.

9(a) In accordance with a proposal of the Remuneration Committee, the Supervisory Board requests the approval of the General Meeting for an amendment of Reed Elsevier's remuneration policy as explained in the letter from the Chairman.

9(b) The combined board recommends and requests approval for increased fees for the members of the Supervisory Board as explained in the letter from the Chairman.

10 **Delegation to the Executive Board of the authority to acquire shares in the Company**

In accordance with the provisions of Article 9 of the Articles of Association, it is proposed that the Executive Board be granted the authority to re-purchase the Company's shares, through stock exchange trading or otherwise, for a period up to and including 30 September 2009, up to the maximum number of shares mentioned in Article 9.2(b) of the Articles of Association, for prices not below the nominal value and not exceeding the higher of (a) 105% of the average market price of the Company's ordinary shares on Euronext Amsterdam during the five trading days immediately preceding the date of the repurchase, (b) the price of the last independent trade of an ordinary share of the Company on Euronext Amsterdam or (c) the then current independent bid for an ordinary share of the Company on Euronext Amsterdam. If the repurchase concerns R-shares, the price shall not be lower than the nominal value and not higher than if calculated on the basis of the price of the ordinary shares in which they can be converted.

11 **Delegation to the combined board of the authority to issue shares, to grant option rights and to restrict pre-emptive rights**

- 11(a) The combined board recommends and proposes to the General Meeting, in accordance with and within the limits of the provisions of Article 6.2 of the Articles of Association, to designate the combined board as the corporate body authorised, during a period which will end on 30 September 2009,
- (i) to issue shares and to grant rights to acquire shares in the capital of the Company, provided this authority shall be limited to 10% of the issued and outstanding share capital of the Company at close of trading on Euronext Amsterdam on 24 April 2008; and furthermore and without application of the 10% limitation,
  - (ii) to issue shares in the capital of the Company in so far as this would be done to meet obligations resulting from the exercise of rights to acquire shares under approved share (option) schemes, it being understood that the authority under (i) and (ii) shall be restricted by the limitations provided in Article 6.2 of the Articles of Association.
- 11(b) In accordance with and within the limits of the provisions of Article 7.4 of the Articles of Association, the General Meeting is proposed to designate the combined board as the corporate body authorised, during a period up to and including 30 September 2009, to restrict or cancel the pre-emptive rights of shareholders at an issue of shares or a grant of rights to acquire shares in the capital of the Company, which are resolved by the combined board.

12. **Other matters**

13. **Close of Meeting**

**Appendices:**

- Appendix A: Notice of the Annual General Meeting  
Appendix B: Biographical details regarding candidates for appointment to the boards  
Appendix C: Travel directions Okura hotel

## Appendix A

### to the Agenda for the Annual General Meeting 2008

#### Notice of Meeting

[translation from original Dutch language version]

#### Annual General Shareholders' Meeting Reed Elsevier N.V.

established at Amsterdam, Radarweg 29, the Netherlands

(Commercial Register Amsterdam nr. 33155037)

to be held on Thursday, 24 April 2008, from 10.30 a.m. CET

in Hotel Okura, Ferdinand Bolstraat 333, Amsterdam, the Netherlands

Shareholders, usufructuaries and holders of a right of pledge over shares with voting rights are hereby invited to attend the meeting. Next is an abridged version of the agenda:

1. Opening
2. Presentation and discussion annual report 2007 and relevant developments
3. Discussion and adoption 2007 annual financial statements
4. Waiver of claims (décharge)
  - 4(a) Waiver of claims against the members of the Executive Board
  - 4(b) Waiver of claims against the members of the Supervisory Board
5. Dividend (Final 2007: €0.311)
6. Appointment of Deloitte Accountants BV as external auditors
7. Changes in the Supervisory Board
  - 7(a) Re-appointment Ms Lisa Hook
8. Changes in the Executive Board
  - 8(a) Re-appointment Sir Crispin Davis
  - 8(b) Re-appointment Gerard van de Aast
  - 8(c) Re-appointment Andrew Prozes
9. Changes remuneration policy and non-executive fees
10. Authority for the Executive Board to acquire shares in the Company
11. Authority for the combined board to issue shares, grant share options and restrict pre-emptive rights
  - 11(a) Authorise the combined board to issue shares and grant share options
  - 11(b) Authorise the combined board to restrict or cancel pre-emptive rights
13. Other matters
14. Close of meeting

The complete agenda and the documents for the meeting as well as a proxy form can be obtained from the offices of the Company and are available from the Reed Elsevier website ([www.reedelsevier.com](http://www.reedelsevier.com)).

#### Admittance and voting rights

Shareholders shall have attendance and voting rights if on Thursday, 27 March 2008 ("the Registration Date"), after processing of all trading transactions on Euronext Amsterdam as of the Registration Date, they are registered as shareholders of the Company with a bank or broker in the Netherlands associated with Euroclear Netherlands.

Shareholders, usufructuaries and holders of a pledge over shares with voting rights, who wish to attend the meeting must procure that a bank or broker in the Netherlands associated with Euroclear Netherlands shall notify ABN AMRO Bank N.V. in the Netherlands (Client desk +31(0)76-579 9455, open between 8 a.m. and 4 p.m. CET, or [servicedesk.beleggen@nl.ABNAMRO.com](mailto:servicedesk.beleggen@nl.ABNAMRO.com)) no later than Thursday, 17 April 2008 that they were shareholder as of the Registration Date and that they wish to attend the meeting and for which number of shares. The shareholder will receive a confirmation of their notification for the meeting. This will serve as admission certificate and upon submission thereof at Hotel Okura prior to the AGM on 24 April 2008, the shareholder respectively their proxy holder will be given access to the meeting.

Shareholders, usufructuaries and holders of a pledge over shares with voting rights, who are registered in person in the Register of Shareholders of the Company at 6 p.m. CET as of the Registration Date will be entitled to attend the AGM if they have notified the Executive Board of the Company in writing (see below correspondence detail) of their attendance. They will receive confirmation of their notification. This will serve as admission certificate and upon submission thereof at Hotel Okura prior to the AGM on 24 April 2008, the shareholder respectively their proxy will be given access to the meeting.

**Representation by proxy**

Subject to compliance with the above provisions, shareholders can attend and vote at the AGM in person or by proxy. Proxies need to be in writing (form available on [www.reedelsevier.com](http://www.reedelsevier.com)) and should at the discretion of the Company sufficiently identify the shareholder and the proxy holder and the number of shares for which the proxy holder will represent the shareholder at the AGM. The proxy must be received by the Company (see below correspondence detail) no later than Monday, 21 April 2008.

Proxy holders representing multiple shareholders whose voting instructions require that they cannot vote individual agenda items similarly for all shares which they represent (for, against, abstain), shall need to contact the Company Secretariat (see the below contact detail) no later than Monday, 21 April 2008, in order to procure appropriate processing of their instructions by the electronic voting system at the AGM.

Shareholders who participate in the Netherlands Shareholders Communication Channel ([www.communicatiekanaal.nl](http://www.communicatiekanaal.nl)) have received a proxy form and instructions by mail. Participants can vote electronically via [www.proxyvote.nl](http://www.proxyvote.nl), using the control number on the voting instruction form which they have received by mail.

**Persons without a valid admission certificate will not be given access to the meeting. Attendants may be asked for identification.**

Amsterdam, 20 March 2008

Combined Board

Communication with the Company regarding the above information through:

Company Secretariat Reed Elsevier N.V.  
Tel. +31(0)20 485 2222, Fax +31 (0)20 485 2032  
P.O. Box 470, 1000 AL Amsterdam  
The Netherlands

## Appendix B

### to the Agenda for the Annual General Meeting 2008

#### **Agenda items 7 and 8: Biographical details of candidates for board appointment**

##### **Lisa Hook (50)**

(American) Appointed 2006. President and Chief Operating Officer of NeuStar Inc. Before that was President and Chief Executive Officer at Sun Rocket Inc. Was President of AOL Broadband, Premium and Developer Services. Prior to joining AOL, was a founding partner at Brera Capital Partners LLC. Previously was Chief Operating Officer of Time Warner Telecom. Has served as Senior Advisor to the Federal Communications Commission Chairman and a Senior Counsel to Viacom Cable. Ms Hook holds no securities in Reed Elsevier NV. Her broad experience in the media industry and her legal background fit the profile for the Supervisory Board.

##### **Sir Crispin Davis (58)**

(British) Chief Executive Officer since 1999. Knighted in 2004 for services to the information industry. Non-executive director of GlaxoSmithKline plc. Prior to joining Reed Elsevier was Chief Executive Officer of Aegis Group plc. From 1990 to 1993 was a member of the main board at Guinness plc and Group Managing Director of United Distillers. Spent over 20 years at Procter and Gamble where he held senior positions in the UK and Germany, before heading up the North American Food Business. For the interest of Sir Crispin in the securities of the Company reference is made to the director's remuneration report 2007.

##### **Gerard van de Aast (50)**

(Dutch) Chief Executive Officer of the Reed Business division since 2000. Member of the supervisory board of Océ N.V. Prior to joining Reed Elsevier was Vice President and General Manager of Compaq's Enterprise business in Europe, Middle East and Africa. For the interest of Mr Van de Aast in the securities of the Company reference is made to the director's remuneration report 2007.

##### **Andrew Prozes (62)**

(Canadian) Chief Executive Officer of the LexisNexis division since 2000. Non-executive director of Cott Corporation. Prior to joining Reed Elsevier was an Executive Vice-President with the West Group, part of the Thomson Corporation, and prior to that was Group President of Southam Inc. For the interest of Mr Prozes in the securities of the Company reference is made to the director's remuneration report 2007.

## **Appendix C**

### **to the Agenda for the Annual General Meeting 2008**

#### **Travel directions Okura hotel**

##### **Public transportation:**

###### **From Central Station:**

tram 25 - stop Cornelis Troostplein or Churchillaan

###### **From Sloterdijk Station:**

tram 12 - stop Cornelis Troostplein or Churchillaan  
bus 15 - stop Scheldestraat/Churchillaan

###### **From Amstel Station:**

tram 12 - stop Cornelis Troostplein or Churchillaan  
bus 15 - stop Scheldestraat/Churchillaan

###### **From Muiderpoort:**

bus 15 - stop Scheldestraat/Churchillaan

###### **From RAI Station:**

From the station turn left; along the roundabout; follow the road straight ahead;  
10 -15 minutes' walk to Hotel Okura

##### **By car:**

###### **From all directions follow Ring A10.**

Exit RAI (S109) and at lights turn right direction RAI/Centrum (S109).

Follow road signs direction Zuid (S109).

At roundabout, via Europaplein, go straight into Scheldestraat.

At lights, crossing Churchillaan, go straight on.

Across the bridge you will see the Okura Hotel (high rise) at your right.

###### **Parking at Okura Hotel**

40 Spaces above ground. 100 Spaces below ground. Limited availability.

Payable parking in the neighbourhood.